Studying Why Some Migraine Patients Respond Poorly to Triptans
Compares tryptophan levels in migraine patients who respond to triptans and those who do not.
Plain-language title generated from the registry record
Registry title: Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Key facts
- Where
- Clermont-Ferrand, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07177885, who can take part
Where in France
- CHU de Clermont-FerrandClermont-Ferrand, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT07177885
- Record updated
- 9 March 2026
- Original description
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.Read full original descriptionShow less
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Inclusion: Cisgender women, premenopausal, aged 18 to 50 years; Cisgender men, aged 18 to 50 years; Diagnosed with migraine (according to ICHD-3 criteria); Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022); Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics); All routes of administration and all dosages; Affiliation with a social security system.
Exclusion: Patients under guardianship, curatorship, deprivation of liberty, or legal protection; Pregnant and breastfeeding women.